Anticonvulsant therapy for status epilepticus

Area of Science:

• Clinical Neurology
• Emergency Medicine
• Pharmacology

Background:

• Status epilepticus (SE) is a life-threatening neurological emergency.
• Effective and safe treatment is crucial to reduce mortality and morbidity.
• Existing literature shows some disagreement on optimal treatment regimens.

Purpose of the Study:

• To compare the efficacy and safety of anticonvulsants for status epilepticus.
• To evaluate treatments against each other and placebo.
• To identify reasons for discrepancies in treatment recommendations and suggest future research directions.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches up to August 2013.
• Inclusion criteria: RCTs of patients with various stages of status epilepticus (premonitory to refractory).
• Data extraction and quality assessment performed independently by two reviewers.

Main Results:

• Intravenous lorazepam demonstrated superior efficacy over placebo and intravenous diazepam/phenytoin in seizure cessation.
• Intramuscular midazolam showed comparable or superior effectiveness to intravenous lorazepam in pre-hospital settings.
• Evidence for other comparisons and long-term adverse effects was limited or uncertain.

Conclusions:

• Intravenous lorazepam is a preferred first-line agent for status epilepticus compared to diazepam or phenytoin.
• Intramuscular midazolam is a viable and potentially more effective option for pre-hospital seizure management.
• Further research is needed due to limited high-quality evidence and uncertainties in treatment comparisons.